<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450395</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1720</org_study_id>
    <nct_id>NCT03450395</nct_id>
  </id_info>
  <brief_title>The Effect of Oats Containing 1.4g Beta Glucan on Fecal Bacterial Population(s) and Plasma Cholesterol in Healthy Adults With Elevated Cholesterol Levels</brief_title>
  <official_title>The Effect of Oats Containing 1.4g Beta Glucan on Fecal Bacterial Population(s) and Plasma Cholesterol in Healthy Adults With Elevated Cholesterol Levels: a Randomized, Single-blind, Placebo-controlled, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to examine fecal bacterial population(s) and plasma&#xD;
      cholesterol levels elicited by 40g of Oats and Cream of Rice over 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2018</start_date>
  <completion_date type="Actual">August 16, 2018</completion_date>
  <primary_completion_date type="Actual">August 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>For each of the two periods, a hot breakfast cereal will be consumed once daily for a duration of 6 weeks each. There will be a 4 week washout period in between each test substance.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal bacterial population(s)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Increase/decrease in desirable fecal bacterial groups (specifically, but not limited to, Bifidobacterium spp. and Lactobacillus/Enterococcus spp.).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal Bile Salt Hydrolase</measure>
    <time_frame>Change from baseline and Week 6</time_frame>
    <description>(ng-μg/g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal bile acid profile</measure>
    <time_frame>Change from baseline Week 6</time_frame>
    <description>(ng-μg/g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal bacterial diversity change</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>Increase/decrease in desirable fecal bacterial groups (specifically, but not limited to, Bifidobacterium spp. and Lactobacillus/Enterococcus spp.). Increase would be better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum FGF-19</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>Fibroblast growth factor (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total Cholesterol</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>mmol/L, lower would be better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma HDL Cholesterol</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>mmol/L, higher would be better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma LDL Cholesterol</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>mmol/L, lower would be better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Triglycerides</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>mmol/L lower would be better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Propionate (propanoic acid)</measure>
    <time_frame>Change from baseline to Week 6</time_frame>
    <description>(µM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Changes from baseline through 6 weeks</time_frame>
    <description>Bowel movements recorded in daily diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stool consistency</measure>
    <time_frame>Changes from baseline through 6 weeks</time_frame>
    <description>Bristol Stool Scale, for each bowel movement, select closest appearance from chart. 7 types ranging from watery to hard lumps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastrointestinal symptoms</measure>
    <time_frame>Changes from baseline through 6 weeks</time_frame>
    <description>Pain, discomfort, bloating &amp; flatulence recorded using subjective GI symptom ranking questionnaire 6 point scale from none to severe for 4 measures: pain, discomfort, bloating, flatulence. No changes would be better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>Changes from baseline through 6 weeks</time_frame>
    <description>SF-36 questionnaire (SF= Short form)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Microbiome</condition>
  <condition>Plasma Cholesterol</condition>
  <condition>Prebiotic</condition>
  <arm_group>
    <arm_group_label>Cereal - Cream of Rice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 g cream of rice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cereal - Oats containing beta-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 g oats</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hot Cereal</intervention_name>
    <description>Intervention involves consumption of one hot cereal in the beginning of each day</description>
    <arm_group_label>Cereal - Cream of Rice</arm_group_label>
    <arm_group_label>Cereal - Oats containing beta-glucan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has given written informed consent;&#xD;
&#xD;
          2. Be between 18 and 65 years of age;&#xD;
&#xD;
          3. Has a BMI of between 18.5 - 30 Kg/m2;&#xD;
&#xD;
          4. Has a stable body weight (&lt; 5% change) over the past 3-months;&#xD;
&#xD;
          5. Have elevated cholesterol levels, with a total cholesterol level &gt;5.5mmol/L and&#xD;
             &lt;7mmol/L; and LDL cholesterol level ≥3.4 mmol/L and ≤4.9 mmol/L.&#xD;
&#xD;
          6. Is in general good health, as determined by the investigator;&#xD;
&#xD;
          7. Consumes a low to moderate fiber diet (9.9 - 25.1 g/day in males; 8.2 - 20.3 g/day in&#xD;
             females);&#xD;
&#xD;
          8. Regularly consumes breakfast;&#xD;
&#xD;
          9. Avoid consuming prebiotic, probiotic or fiber rich supplements within 3 weeks prior to&#xD;
             baseline visit, until the end of the study;&#xD;
&#xD;
         10. Avoid consumption of any whole grain oat products, within 3 weeks prior to baseline&#xD;
             visit, until the end of the study;&#xD;
&#xD;
         11. Agrees to continue to consume the same dose of vitamin and/or mineral supplements, if&#xD;
             applicable, for the duration of the study;&#xD;
&#xD;
         12. Maintain current level of physical activity;&#xD;
&#xD;
         13. Agree to keep detailed dietary and stool records;&#xD;
&#xD;
         14. Willing to consume the investigational products daily for the duration of the study.&#xD;
&#xD;
         15. Subject must have access to a microwave oven&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females are pregnant, lactating or wish to become pregnant during the study. Female&#xD;
             subject is currently either of:&#xD;
&#xD;
               -  non-childbearing potential (i.e., physiologically incapable of becoming pregnant,&#xD;
                  including any female who is post-menopausal or any female who is surgically&#xD;
                  sterilized (via documented hysterectomy or bilateral tubal ligation). (For&#xD;
                  purposes of this study, postmenopausal is defined as one year without menses), OR&#xD;
&#xD;
               -  child bearing potential, the subject is eligible to enter and participate in this&#xD;
                  study if she is not lactating and has a negative urine pregnancy test at the&#xD;
                  screening visit, visit 2 and upon completion of the study at visit 7. The subject&#xD;
                  must also agree to one of the following methods of contraception: i. Complete&#xD;
                  abstinence from intercourse two weeks prior to administration of study drug,&#xD;
                  throughout the clinical trial, until the completion of follow-up procedures or&#xD;
                  for two weeks following discontinuation of the study medication in cases where&#xD;
                  subject discontinues the study prematurely. (Subjects utilizing this method must&#xD;
                  agree to use an alternate method of contraception if they should become sexually&#xD;
                  active and will be queried on whether they have been abstinent in the preceding 2&#xD;
                  weeks when they present to the clinic for the Final Visit.) or, ii. has a male&#xD;
                  sexual partner who is surgically sterilized prior to the Screen Visit and is the&#xD;
                  only male sexual partner for that subject or, iii. sexual partner(s) is/are&#xD;
                  exclusively female or, iv. Oral contraceptives (either combined or progestogen&#xD;
                  only) with double-barrier method of contraception consisting of spermicide with&#xD;
                  either condom or diaphragm. (Women of child-bearing potential using an oral&#xD;
                  contraceptive in combination with a double-barrier method of contraception are&#xD;
                  required to continue to use this form of contraception for 1 week following&#xD;
                  discontinuation of study medication).&#xD;
&#xD;
                  v. Use of double-barrier contraception, specifically, a spermicide plus a&#xD;
                  mechanical barrier (e.g. male condom, female diaphragm). The subject must be&#xD;
                  using this method for at least 1 week following the end of the study or, vi. Use&#xD;
                  of any intrauterine device (IUD) or contraceptive implant with published data&#xD;
                  showing that the highest expected failure rate is less than 1% per year. The&#xD;
                  subject must have the device inserted at least 2 weeks prior to the first Screen&#xD;
                  Visit, throughout the study, and 2 weeks following the end of the study,&#xD;
&#xD;
          2. Are hypersensitive to any of the components of the test products;&#xD;
&#xD;
          3. Is Coeliac, or has an intolerance to gluten;&#xD;
&#xD;
          4. Has taken antibiotics within the previous 3 months;&#xD;
&#xD;
          5. Has a history of drug and/or alcohol abuse at the time of enrolment;&#xD;
&#xD;
          6. Consumes greater than 2 servings/day of alcohol (e.g. &gt;28 g ethanol/day);&#xD;
&#xD;
          7. Is a smoker;&#xD;
&#xD;
          8. Has a fasting blood glucose level outside the range of 3.0 - 6.0 mmol/L;&#xD;
&#xD;
          9. Has uncontrolled hypertension (systolic blood pressure ≥159 mm Hg or diastolic blood&#xD;
             pressure ≥99 mm Hg);&#xD;
&#xD;
         10. Has made any major dietary changes in the past 3 months;&#xD;
&#xD;
         11. Planned major changes in life style (i.e. diet, dieting, exercise level, travelling)&#xD;
             during the duration of the study;&#xD;
&#xD;
         12. Has a diagnosed eating disorder;&#xD;
&#xD;
         13. Is vegetarian/vegan diet or has food allergies or other issues with foods that would&#xD;
             preclude intake of the study products;&#xD;
&#xD;
         14. Taking a medication/supplement that the investigator believes would impart or treat&#xD;
             constipation, including iron, Imodium, Colon Clean, chronic or regular laxatives use&#xD;
             or dependency on laxatives; and fiber supplements, within 3 weeks prior to baseline&#xD;
             visit, until the end of the study;&#xD;
&#xD;
         15. Has an active gastrointestinal disorder or previous gastrointestinal surgery, other&#xD;
             than an appendectomy&#xD;
&#xD;
         16. If taking chronic medications (e.g., hypertensive medications), they must have been&#xD;
             taking the product for at least two months prior to screening and agree to maintain&#xD;
             the same dosage throughout the study;&#xD;
&#xD;
         17. Subject is on any medication that has an effect on lowering cholesterol, such as use&#xD;
             of beta blockers to treat hypertension or anxiety;&#xD;
&#xD;
         18. Has a metabolic or gastrointestinal diseases (i.e., diarrhea, Crohn's disease,&#xD;
             ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal&#xD;
             ulcers, diabetes, hepatitis, HIV, cancer, etc.), with a history of such diseases;&#xD;
&#xD;
         19. Has a condition or taking a medication that the investigator believes would interfere&#xD;
             with the objectives of the study, pose a safety risk or confound the interpretation of&#xD;
             the study results; to include Statins (including atorvastatin (Lipitor and Torvast),&#xD;
             fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin (Livalo,&#xD;
             Pitava), pravastatin (Pravachol, Selektine, Lipostat), rosuvastatin (Crestor) and&#xD;
             simvastatin (Zocor, Lipex)), Cholesterol Absorption Inhibitors (including Zetia&#xD;
             (ezetimibe)), Niacin (nicotinic acid), Fibric acid derivatives (including Atromid-S&#xD;
             (clofibrate), Lopid (gemfibrozil), and Tricor (fenofibrate)), Bile Acid Sequestrants&#xD;
             (including cholestyramine, sold under the brand names Questran, Prevalite, and&#xD;
             LoCholest, and colestipol (Colestid)) and Non Steroidal Anti-Inflammatory Drugs&#xD;
             (NSAIDs), or have taken them in the past 28 days;&#xD;
&#xD;
         20. Taking a cholesterol lowering supplement, including, example Plant sterols/stanols,&#xD;
             Fish Oil supplements, vitamin B supplements (e.g. Niacin and Niacinamide), red rice&#xD;
             yeast extract, oat beta glucan, pharmaceutical garlic or have taken them in the past&#xD;
             month;&#xD;
&#xD;
         21. Are severely immunocompromised (HIV positive, transplant patient, on antirejection&#xD;
             medications, on a steroid for &gt;30 days, or chemotherapy or radiotherapy within the&#xD;
             last year);&#xD;
&#xD;
         22. Experiences alarm features such as weight loss, rectal bleeding, recent change in&#xD;
             bowel habit (&lt;3 months) or abdominal pain;&#xD;
&#xD;
         23. Have a malignant disease or any concomitant end-stage organ disease;&#xD;
&#xD;
         24. Individuals who, in the opinion of the investigator, are considered to be poor&#xD;
             attendees or unlikely for any reason to be able to comply with the trial;&#xD;
&#xD;
         25. Subjects may not be receiving treatment involving experimental drugs. If the subject&#xD;
             has been in a recent experimental trial, these must have been completed not less than&#xD;
             60 days prior to this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Dinan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cork University Hospital &amp; APC Microbiome Institute, University College Cork</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <zip>T12 H2TK</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

